Owing to the heterogeneity of BLCA and the tight associations between molecular subtypes and patients’ prognosis and treatment outcomes, the molecular subtypes of patients with different MTHFD2 expression levels were analyzed based on seven classification systems. Here, MTHFD2 is linked to bladder transitional cell carcinoma.